

4

Attorney Docket No.: 5994.504-US

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application Commissioner for Patents 2900 Crystal Drive Arlington, VA 22202-3513



Express Mail Label No. EL 049071886US Date of Deposit January 14, 2002

Sir:

This is a request for filing a patent application under 37 C.F.R. 1.53(b) of

Applicant(s): Ezban et al.

Title: Use of FVIIa or a Tissue Factor Antagonist for Regulating Gene

Expression and Cell Migration or Chemotaxis

31 pages of specification 1 page of abstract

18 sheets of Formal Drawings

3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee: \$740.00

Total Claims:  $6 - 20 = 0 \times 18 =$  \$0

Independent Claims:  $1 - 3 = 0 \times 84 =$ \$0

Total Fee: \$740.00

Priority of Danish application nos. PA 1999 01117 and PA 1999 01023 filed on August 12, 1999 and July 14, 1999, respectively, is claimed under 35 U.S.C. 119. A certified copy of each application will be submitted at a later date.

Priority of U.S. provisional application no. 60/148,300 filed on August 11, 1999 is claimed under 35 U.S.C. 119.

The benefit of application no. PCT/DK00/00401 filed on July 14, 2000 in the PCT is claimed under 35 U.S.C. 120.

Address all future communications to Reza Green, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$740, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: January 14, 2002

Reza Green, Reg. No. 38,475

Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123

Attorney Docket No.: 5994.504-US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## **EXPRESS MAIL CERTIFICATE**

Box Patent Application Commissioner for Patents 2900 Crystal Drive Arlington, VA 22202-3513

Re: U.S. Patent Application for

Title: Use of FVIIa or a Tissue Factor Antagonist for Regulating Gene

Expression and Cell Migration or Chemotaxis

Applicants: Ezban et al.

Sir:

Express Mail Label No. EL 049071886US

Date of Deposit: January 14, 2002

I hereby certify that the following attached paper(s) or fee

- 1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
- 2. Patent Application (with 18 sheets of Formal Drawings)
- 3. Unexecuted Combined Declaration and Power of Attorney
- 4. Preliminary Amendment
- 5. Information Disclosure Statement
- 6. Form PTO-1449
- 7. Copy of References

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, 2900 Crystal Drive, Arlington, VA 22202-3513.

Carol McFarlane-Fishberg

(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address: Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10017 (212) 867-0123